Literature DB >> 35738631

The Modified Glasgow Prognostic Score and Prognostic Nutritional Index as Prognostic Markers in Patients With Metastatic Breast Cancer Treated With Eribulin.

Shinya Yamamoto1, Shoko Adachi2, Tomoko Wada2, Kazutaka Narui2, Aki Kimura3, Masanori Oshi3, Akimitsu Yamada3, Toshihiro Misumi4, Itaru Endo3.   

Abstract

AIM: To examine the role of the Modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) as prognostic markers for patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: We investigated the associations of clinico-pathological factors with time-to-treatment failure (TTF) and overall survival (OS) in 110 patients with MBC treated with eribulin.
RESULTS: C-Reactive protein >1 mg/dl, albumin <3.5 g/dl, mGPS=2, and PNI <40 were significant predictors of shorter TTF in univariate analyses. PNI <40 remained a significant and independent predictor of shorter TTF in multivariate analyses. De novo tumor, visceral metastases, C-reactive protein >1 mg/dl, albumin <3.5 g/dl, mGPS=2, and PNI <40 were significant predictors of poor OS at the univariate level. A PNI <40 was a significant and independent predictor of poor OS in multivariate analyses.
CONCLUSION: PNI is a reliable predictor of TTF and OS in patients with MBC treated with eribulin.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; eribulin; modified Glasgow Prognostic Score; prognostic marker; prognostic nutritional index

Mesh:

Substances:

Year:  2022        PMID: 35738631      PMCID: PMC9301441          DOI: 10.21873/invivo.12903

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  21 in total

1.  Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.

Authors:  Yudai Ishiyama; Tsunenori Kondo; Yuki Nemoto; Yuki Kobari; Hiroki Ishihara; Hidekazu Tachibana; Kazuhiko Yoshida; Yasunobu Hashimoto; Toshio Takagi; Junpei Iizuka; Kazunari Tanabe
Journal:  Anticancer Res       Date:  2021-03       Impact factor: 2.480

2.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

Review 3.  Estrogen and progesterone receptors in breast cancer.

Authors:  Cheng-Har Yip; Anthony Rhodes
Journal:  Future Oncol       Date:  2014-11       Impact factor: 3.404

4.  Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.

Authors:  Yoichi Koyama; Saori Kawai; Natsuki Uenaka; Miki Okazaki; Mariko Asaoka; Saeko Teraoka; A I Ueda; Kana Miyahara; Takahiko Kawate; Hiroshi Kaise; Kimito Yamada; Takashi Ishikawa
Journal:  Cancer Diagn Progn       Date:  2021-11-03

5.  Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.

Authors:  San-gang Wu; Zhen-yu He; Juan Zhou; Jia-yuan Sun; Feng-yan Li; Qin Lin; Ling Guo; Huan-xin Lin
Journal:  Breast       Date:  2013-12-02       Impact factor: 4.380

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.

Authors:  Yoshimasa Miyagawa; Kazuhiro Araki; Ayako Bun; Hiromi Ozawa; Yukie Fujimoto; Tomoko Higuchi; Arisa Nishimukai; Ayako Kira; Michiko Imamura; Yuichi Takatsuka; Yasuo Miyoshi
Journal:  Clin Breast Cancer       Date:  2018-03-08       Impact factor: 3.225

8.  Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.

Authors:  Wataru Goto; Shinichiro Kashiwagi; Yuka Asano; Koji Takada; Tamami Morisaki; Hisakazu Fujita; Tsutomu Takashima; Masahiko Ohsawa; Kosei Hirakawa; Masaichi Ohira
Journal:  Anticancer Res       Date:  2018-05       Impact factor: 2.480

9.  High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.

Authors:  Yasuo Miyoshi; Yuta Yoshimura; Kenichi Saito; Kenzo Muramoto; Michiko Sugawara; Karenza Alexis; Kenichi Nomoto; Seigo Nakamura; Toshiaki Saeki; Junichiro Watanabe; Jose Manuel Perez-Garcia; Javier Cortes
Journal:  Breast Cancer       Date:  2020-03-05       Impact factor: 4.239

10.  Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; W J Angerson; D J Dunlop
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.